Mild Cognitive Impairment Clinical Trial
Official title:
Examining the Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance in Patients Undergoing Neuroimaging Evaluation for Cognitive Decline: A Double-blinded Placebo Controlled Expansion Study
Verified date | February 2023 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Constituents of grapes have been studied for their antioxidant, anti-inflammatory, and anticarcinogenic properties. In the past decade, there has been emerging evidence regarding a potential role for grapes in slowing cognitive decline and other effects of aging. Furthermore, evidence has been obtained in vivo that supplementation with grape seed extract in aged rats improves cognitive performance, and that supplementation with grapes in people having decline in cognition leads to preservation of metabolism in brain regions important to cognitive function over a period of six months. The investigator aims to measure effects of grape intake on cerebral metabolism and neuropsychological performance, and to determine whether initial patterns, and magnitude of change, of cerebral metabolism assessed by positron emission tomography (PET) can serve respectively as a predictor of, and biomarker for, the magnitude of cognitive changes resulting from intake of grapes over a period of at least one year.
Status | Completed |
Enrollment | 32 |
Est. completion date | October 15, 2022 |
Est. primary completion date | October 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years to 85 Years |
Eligibility | Inclusion Criteria: - Referred to the UCLA NeuroPET Clinics for concern of cognitive decline and/or behavioral changes. - Standard history, physical, and laboratory screen performed to identify possible presence of depression, substance abuse, malnourishment, medical effects and interactions, cardiopulmonary compromise, electrolyte/calcium imbalance, anemia, hypoxemia, infection, thyroid dysfunction, renal dysfunction, hepatic dysfunction, or glucose dysregulation, and appropriate therapies administered (if any). - Appropriate neurological consultation has been obtained, as well as CT/MRI and/or neurosurgical consultation if history or neurologic exam reveal findings suspicious for stroke, tumor, bleed, ictal activity, or hydrocephalus. Exclusion Criteria: - Subjects under age 65 and over age 85, in order to enhance the clinical relevance of the project by focusing on the age groups in whom serious concerns about early signs and symptoms of senile onset dementia are most typically emerging. - Have begun cholinesterase inhibitors or memantine in the last 6 months. - Patient lacks adequate functional status and/or caregiver support to reliably follow grape consumption regimen. - Claustrophobia or other condition that would preclude PET from being acquired, or visual, auditory, language, or motor deficits that would preclude accurate neuropsychological testing. - Non-English speaking subjects, due to lack of neuropsychologic testing or equivalent instruments in non-English languages. - Subjects with a history of allergy to grapes or grape products. |
Country | Name | City | State |
---|---|---|---|
United States | University of California, Los Angeles | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | California Table Grape Commission |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Regional Cerebral Metabolism | Changes from baseline in regional cerebral metabolism | Baseline and 12 months | |
Secondary | Changes in neuropsychological performance measures | Changes in cognitive performance over time within each group will be measured through the neuropsychological assessments listed below, as administered by trained psychometrists under direct supervision of a licensed neuropsychologist, and will be correlated with changes in regional cerebral metabolism. | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Mini-Mental State Examination | Mini-Mental State Examination (Folstein, 1975) | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Wechsler Adult Intelligence Scale (WAIS-III) Digit Span | Wechsler Adult Intelligence Scale (WAIS-III) Digit Span (Wechsler, 1997) | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Trail Making Test Part B | Trail Making Test Part B (Reitan, 1958) | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Functional Activities Questionnaire | Functional Activities Questionnaire (Pfeffer et al., 1982) | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Verbal Memory | NeuroTrax BrainCare, a cloud-based computer application that includes a series of tests and associated reports, will be used to measure Verbal Memory. | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Non-Verbal Memory | Non-Verbal Memory (measured using the NeuroTrax BrainCare application) | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Verbal Function | Verbal Function (measured using the NeuroTrax BrainCare application) | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Stroop Interference | Stroop Interference (measured using the NeuroTrax BrainCare application) | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Problem Solving | Problem Solving (measured using the NeuroTrax BrainCare application) | Baseline, 6 months, and 12 months | |
Secondary | Changes in neuropsychological performance measures: Visual Spatial Processing | Visual Spatial Processing (measured using the NeuroTrax BrainCare application) | Baseline, 6 months, and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |